Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. Therapies targeted against stromal targets in the tumour microenvironment are now in pre-clinical and clinical trial. Here, we focus on our recent findings in autochthonous models of PDAC that suggest CXCR2 expressed on neutrophils is important in establishing immunosuppression in the primary tumour and the metastatic niche at distant sites. We discuss CXCR2 as a potential therapeutic target in the context of other potential stromal targets in PDAC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
